Literature DB >> 21658003

Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides.

Wenjing Zhao1, Scott A McCallum, Zhongping Xiao, Fuming Zhang, Robert J Linhardt.   

Abstract

Heparin and HS (heparan sulfate) exert their wide range of biological activities by interacting with extracellular protein ligands. Among these important protein ligands are various angiogenic growth factors and cytokines. HS binding to VEGF (vascular endothelial growth factor) regulates multiple aspects of vascular development and function through its specific interaction with HS. Many studies have focused on HS-derived or HS-mimicking structures for the characterization of VEGF165 interaction with HS. Using a heparinase 1-prepared small library of heparin-derived oligosaccharides ranging from hexasaccharide to octadecasaccharide, we systematically investigated the heparin-specific structural features required for VEGF binding. We report the apparent affinities for the association between the heparin-derived oligosaccharides with both VEGF165 and VEGF55, a peptide construct encompassing exclusively the heparin-binding domain of VEGF165. An octasaccharide was the minimum size of oligosaccharide within the library to efficiently bind to both forms of VEGF and a tetradecasaccharide displayed an effective binding affinity to VEGF165 comparable to unfractionated heparin. The range of relative apparent binding affinities among VEGF and the panel of heparin-derived oligosaccharides demonstrate that the VEGF binding affinity likely depends on the specific structural features of these oligosaccharides, including their degree of sulfation, sugar-ring stereochemistry and conformation. Notably, the unique 3-O-sulfo group found within the specific antithrombin binding site of heparin is not required for VEGF165 binding. These findings afford new insight into the inherent kinetics and affinities for VEGF association with heparin and heparin-derived oligosaccharides with key residue-specific modifications and may potentially benefit the future design of oligosaccharide-based anti-angiogenesis drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21658003      PMCID: PMC3190640          DOI: 10.1042/BSR20110077

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  54 in total

1.  VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.

Authors:  Christopher J Robinson; Barbara Mulloy; John T Gallagher; Sally E Stringer
Journal:  J Biol Chem       Date:  2005-10-28       Impact factor: 5.157

2.  Structural features in heparin that interact with VEGF165 and modulate its biological activity.

Authors:  K Ono; H Hattori; S Takeshita; A Kurita; M Ishihara
Journal:  Glycobiology       Date:  1999-07       Impact factor: 4.313

Review 3.  Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.

Authors:  Neta Ilan; Michael Elkin; Israel Vlodavsky
Journal:  Int J Biochem Cell Biol       Date:  2006-07-06       Impact factor: 5.085

Review 4.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

5.  Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia.

Authors:  D Mikhailov; H C Young; R J Linhardt; K H Mayo
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

6.  Heparin accelerates gelsolin amyloidogenesis.

Authors:  Ji Young Suk; Fuming Zhang; William E Balch; Robert J Linhardt; Jeffery W Kelly
Journal:  Biochemistry       Date:  2006-02-21       Impact factor: 3.162

Review 7.  Vascular endothelial growth factor (VEGF) inhibition--a critical review.

Authors:  Irina Sousa Moreira; Pedro Alexandrino Fernandes; Maria João Ramos
Journal:  Anticancer Agents Med Chem       Date:  2007-03       Impact factor: 2.505

8.  Kinetic and structural studies on interactions between heparin or heparan sulfate and proteins of the hedgehog signaling pathway.

Authors:  Fuming Zhang; Jason S McLellan; Alondra M Ayala; Daniel J Leahy; Robert J Linhardt
Journal:  Biochemistry       Date:  2007-03-10       Impact factor: 3.162

9.  Heparin octasaccharides inhibit angiogenesis in vivo.

Authors:  Jurjees Hasan; Steven D Shnyder; Andrew R Clamp; Alan T McGown; Roy Bicknell; Marco Presta; Michael Bibby; John Double; Steven Craig; David Leeming; Kenneth Stevenson; John T Gallagher; Gordon C Jayson
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

10.  Synthetic oligosaccharide stimulates and stabilizes angiogenesis: structure-function relationships and potential mechanisms.

Authors:  S A Mousa; X Feng; J Xie; Y Du; Y Hua; H He; L O'Connor; R J Linhardt
Journal:  J Cardiovasc Pharmacol       Date:  2006-08       Impact factor: 3.271

View more
  27 in total

1.  Synergistic Binding of Vascular Endothelial Growth Factor-A and Its Receptors to Heparin Selectively Modulates Complex Affinity.

Authors:  Madelane Teran; Matthew A Nugent
Journal:  J Biol Chem       Date:  2015-05-15       Impact factor: 5.157

2.  Fucoidan in a 3D scaffold interacts with vascular endothelial growth factor and promotes neovascularization in mice.

Authors:  Agung Purnama; Rachida Aid-Launais; Oualid Haddad; Muriel Maire; Diego Mantovani; Didier Letourneur; Hanna Hlawaty; Catherine Le Visage
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

Review 3.  Design of growth factor sequestering biomaterials.

Authors:  David G Belair; Ngoc Nhi Le; William L Murphy
Journal:  Chem Commun (Camb)       Date:  2014-09-03       Impact factor: 6.222

4.  RNAscope for VEGF-A Detection in Human Tumor Bioptic Specimens.

Authors:  Tiziana Annese; Roberto Tamma; Domenico Ribatti
Journal:  Methods Mol Biol       Date:  2022

5.  New anti-angiogenic compound based on chemically modified heparin.

Authors:  Vinicius Kniggendorf; Maria Eduarda Perrud Souza; Thatiane Russo; Marcelo Andrade de Lima; Alex Treiger Grupenmacher; Caio V Regatieri; Juliana L Dreyfuss
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-09-13       Impact factor: 3.535

6.  Multifunctional silk-heparin biomaterials for vascular tissue engineering applications.

Authors:  F Philipp Seib; Manuela Herklotz; Kelly A Burke; Manfred F Maitz; Carsten Werner; David L Kaplan
Journal:  Biomaterials       Date:  2013-10-04       Impact factor: 12.479

7.  Mechanism of action and efficacy of RX-111, a thieno[2,3-c]pyridine derivative and small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs), in delayed-type hypersensitivity, TNBS-induced colitis and experimental autoimmune encephalomyelitis.

Authors:  Nicholas Harris; Juraj Koppel; Ferenc Zsila; Stefan Juhas; Gabriela Il'kova; Faina Yurgenzon Kogan; Orly Lahmy; Gizi Wildbaum; Nathan Karin; Regina Zhuk; Paul Gregor
Journal:  Inflamm Res       Date:  2016-01-21       Impact factor: 4.575

8.  Heparin-modified alginate microspheres enhance neovessel formation in hiPSC-derived endothelial cells and heterocellular in vitro models by controlled release of vascular endothelial growth factor.

Authors:  Fabiola Munarin; Carly Kabelac; Kareen L K Coulombe
Journal:  J Biomed Mater Res A       Date:  2021-03-17       Impact factor: 4.854

9.  Site-Specific Phosphorylation of VEGFR2 Is Mediated by Receptor Trafficking: Insights from a Computational Model.

Authors:  Lindsay Wendel Clegg; Feilim Mac Gabhann
Journal:  PLoS Comput Biol       Date:  2015-06-12       Impact factor: 4.475

10.  Heparan sulfate proteoglycans undergo differential expression alterations in right sided colorectal cancer, depending on their metastatic character.

Authors:  Iván Fernández-Vega; Olivia García-Suárez; Beatriz García; Ainara Crespo; Aurora Astudillo; Luis M Quirós
Journal:  BMC Cancer       Date:  2015-10-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.